Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 701–800 of 1,000
Link Prediction through Deep Generative Model
Wang, X., Chen, Y., & Liu, Y. (2020) · iScience · doi:10.1016/j.isci.2020.101626 · Cited by 16
Manen-Freixa, L., & Antolín, A. A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2376643 · Cited by 15
“The demonstration that off-targets could be identified using side-effect similarity was a landmark study that opened a new area of research [252].”
A machine-learned computational functional genomics-based approach to drug classification
Lötsch, J., & Ultsch, A. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2134-x · Cited by 15
“For example, the identification of unknown drug targets was shown to be possible from side effect similarities obtained via querying the Unified Medical Language System (UMLS) ontology for medical symptoms [35].”
MethodPredicting Drug-target Interaction via Wide and Deep Learning
Du, Y., Wang, J., Wang, X., Chen, J., & Chang, H. (2018) · International Conference on Bioinformatics and Computational Biology (ICBCB) · doi:10.1145/3194480.3194491 · Cited by 15
“Traditional methods for predicting DTIs previously include docking simulation [3][4] and ligand-based approaches [5][6].”
MethodA Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning
Huang, C.-T., Hsieh, C.-H., Oyang, Y.-J., Huang, H., & Juan, H. (2018) · iScience · doi:10.1016/j.isci.2018.08.017 · Cited by 16
Development of an adverse drug event network to predict drug toxicity
Wu, Q., Taboureau, O., & Audouze, K. (2020) · Current Research in Toxicology · doi:10.1016/j.crtox.2020.06.001 · Cited by 15
“constructed a drug-target-SE network, and demonstrated that drugs with similar side-effect profile have a similar protein target profile (Campillos et al., 2008).”
BackgroundShang, Y., Ye, X., Futamura, Y., Yu, L., & Sakurai, T. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac059 · Cited by 16
Prediction of drug side effects with transductive matrix co-completion
Liang, X., Fu, Y., Qu, L., Zhang, P., & Chen, Y. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad006 · Cited by 16
Role of Text Mining in Early Identification of Potential Drug Safety Issues
Liu, M., Hu, Y. Q., & Tang, B. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0709-0_13 · Cited by 17
PhIN: A Protein Pharmacology Interaction Network Database
Wang, Z., Li, J., Dang, R., Liang, L., & Lin, J. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.25 · Cited by 16
“Molecule–molecule functional similarity Drugs with overlapping drug targets are likely to be side effect similar.(35,36) Therefore, PhIN introduces molecule– molecule functional similarity by defining that functional similarity of two molecules is determined by their interactive targets in common (the default threshol…”
BackgroundMany Approved Drugs Have Bioactive Analogs With Different Target Annotations
Hu, Y., Lounkine, E., & Bajorath, J. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9621-8 · Cited by 15
Arany, Á., Bolgár, B., Balogh, B., Antal, P., & Mátyus, P. (2012) · Current Medicinal Chemistry · doi:10.2174/09298673130110 · Cited by 16
O’Meara, M. J., Ballouz, S., Shoichet, B. K., & Gillis, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160098 · Cited by 16
Ling, L., Yao, C., Du, Y., Ismail, M., He, R., Hou, Y., Zhang, Y., & Li, X. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0396 · Cited by 15
Bioinformatics Approaches to Predict Drug Responses from Genomic Sequencing
Madhukar, N. S., & Elemento, O. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7493-1_14 · Cited by 18
Discovering Putative Protein Targets of Small Molecules: A Study of the p53 Activator Nutlin
Nguyen, M. N., Sen, N., Lin, M., Joseph, T. L., Vaz, C., Tanavde, V., Way, L., Hupp, T. R., Verma, C. S., & Madhusudhan, M. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00762 · Cited by 15
Predicate Oriented Pattern Analysis for Biomedical Knowledge Discovery
Shen, F., Liu, H., Sohn, S., Larson, D. W., & Lee, Y. (2016) · Intelligent Information Management · doi:10.4236/iim.2016.83006 · Cited by 14
“[51] were able to identify a drug target by using side-effect similarity, and thus found association among the drug, target, and side effect.”
BackgroundQian, Y., Wang, Y., Liu, J., Zou, Q., Ding, Y., Guo, X., & Ding, W. (2024) · Information Fusion · doi:10.1016/j.inffus.2024.102894 · Cited by 15
Xu, R., & Wang, Q. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s5-s6 · Cited by 14
“It has been increasingly recognized that similar side effects of seemingly unrelated drugs can be caused by their common off-targets and that drugs with similar side effects are likely to share molecular targets [1].”
BackgroundVilar, S., & Hripcsak, G. M. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0147-1 · Cited by 16
“Campillos et al. [16] used adverse drug reactions profiles to develop a target identification model validated experimentally.”
BackgroundPIMD: An Integrative Approach for Drug Repositioning using Multiple Characterization Fusion
He, S., Wen, Y., Yang, X., Liu, Z., Song, X., Huang, X., & Bo, X. (2020) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.10.012 · Cited by 14
Primum non nocere: In silico prediction of adverse drug reactions of antidepressant drugs
Güneş, S. S., Yeşil, Ç., Gürdal, E. E., Korkmaz, E. E., Yarım, M., Aydın, A., & Sipahi, H. (2021) · Computational Toxicology · doi:10.1016/j.comtox.2021.100165 · Cited by 15
Deciding when to stop: efficient experimentation to learn to predict drug-target interactions
Temerinac-Ott, M., Naik, A. W., & Murphy, R. F. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0650-9 · Cited by 14
“Several methods for drug-target prediction without active learning have been proposed recently [11–17] and remain an active area of research.”
MethodXu, R., & Wang, Q. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.10.002 · Cited by 15
“Current systems approaches to studying phenotypic relationships among drugs rely exclusively on information extracted from FDA drug labels [3,5,17].”
BackgroundInfluentialAn Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer
Ramanathan, K., Verma, K., Sequeira, V. M., Basavanna, L. N., & Veerappapillai, S. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25799 · Cited by 14
Kunimoto, R., Dimova, D., & Bajorath, J. (2017) · ACS Omega · doi:10.1021/acsomega.7b00215 · Cited by 14
“For example, drug-target networks 8,9 establish compound-based links between targets and help to better understand complex interactions involving multiple compounds and targets.”
BackgroundDrug—target interaction prediction with a deep-learning-based model
Xie, L., Zhang, Z., He, S., Bo, X., & Song, X. (2017) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2017.8217693 · Cited by 14
“In addition to cellular response data, researchers tried using side effect data, chemical data, and pharmacological data to identify the novel interactions between drugs and target proteins [6], [10], [11].”
BackgroundBioGPS: The Music for the Chemo‐ and Bioinformatics Walzer
Siragusa, L., Spyrakis, F., Goracci, L., Cross, S., & Cruciani, G. (2014) · Molecular Informatics · doi:10.1002/minf.201400028 · Cited by 14
Rocca, E., Anjum, R. L., & Mumford, S. D. (2020) · Boston studies in the philosophy of science · doi:10.1007/978-3-030-29179-2_2 · Cited by 15
Park, S., Lee, S., Pak, M., & Kim, S. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3350083 · Cited by 15
“Some studies have found drug targets using side effect information [34], [39], while others investigated drug protein target to explain the side effects of the drugs [40], [41], [42].”
Yuan, Y., Zhang, Y., Meng, X., Liu, Z., Wang, B., Miao, R., Zhang, R., Su, W., & Liu, L. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108498 · Cited by 14
Mining hidden knowledge for drug safety assessment: topic modeling of LiverTox as a case study
Yu, K., Zhang, J., Chen, M., Xu, X., Suzuki, A., Ilić, K., & Tong, W. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s17-s6 · Cited by 15
“These databases contribute significantly to the research community, facilitating the enhanced understanding of drug safety issues [3].”
BackgroundComputational Study of Drugs by Integrating Omics Data with Kernel Methods
Wang, Y. C., 邓, 乃., Chen, S., & Wang, Y. (2013) · Molecular Informatics · doi:10.1002/minf.201300090 · Cited by 13
Wada, A., Hara, S., & Osada, H. (2014) · Analytical Chemistry · doi:10.1021/ac4030208 · Cited by 14
Muthas, D., & Boyer, S. K. (2013) · Molecular Informatics · doi:10.1002/minf.201200088 · Cited by 13
Learning disease relationships from clinical drug trials
Haslam, B., & Perez-Breva, L. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw003 · Cited by 13
“Campillos et al. 12 and Tatonetti et al. 13 compared drugs based on shared side effects.”
Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases
Liu, Z., Fang, H., Slikker, W., & Tong, W. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.010 · Cited by 13
Gomes, A., Fernandes, I., Teixeira, C. A. S., Mateus, N. F. D. C. B., Sottomayor, M. J., & Gomes, P. A. C. (2016) · ChemMedChem · doi:10.1002/cmdc.201600477 · Cited by 13
Systems Pharmacogenomic Landscape of Drug Similarities from LINCS data: Drug Association Networks
Musa, A., Tripathi, S., Dehmer, M., Yli-Harja, O. P., Kauffman, S. A., & Emmert‐Streib, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-44291-3 · Cited by 17
Safe, effective and explainable drug recommendation based on medical data integration
Symeonidis, P., Chairistanidis, S., & Zanker, M. (2022) · User Modeling and User-Adapted Interaction · doi:10.1007/s11257-022-09342-x · Cited by 15
“In addition, related work (Campillos et al. 2008) has tried to find relevance between drugs based on common chemical compounds or sequence similarity of their known targets.”
BackgroundInfluentialDrug-drug interaction analysis using heterogeneous biological information network
Lee, K., Lee, S., Jeon, M., Choi, J., & Kang, J. (2012) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2012.6392634 · Cited by 13
Personalized Medicine: the Impact on Chemistry
Watkins, J., Marsh, A., Taylor, P. C., & Singer, D. R. J. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.64 · Cited by 16
An Efficient Drug-Target Interaction Mining Algorithm in Heterogeneous Biological Networks
Li, C., Sun, J., Xiong, Y., & Zheng, G. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-13186-3_7 · Cited by 13
“For example, Campillos and Monica proposed a method for identifying drug target genes by the similarity of side effects [4].”
MethodKaratzas, E., Kakouri, A. C., Kolios, G. C., Delis, A., & Spyrou, G. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249687 · Cited by 12
“We prioritize substances dissimilar to already-failed drugs, since drugs with similar structures tend to have similar mode of action [14].”
BackgroundMethodChen, Y.-H., Shih, Y.-T., Chien, C. ‐., & Tsai, C.-S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266435 · Cited by 13
“Established algorithms have used existing molecular biology databases 14 such as gene expression and drug chemical properties to predict drug performance and 15 possible side effects [10,11], and the others have exploited internet search-keywords to 16 infer potential side effects for monitoring drug safety [12].”
Zhang, J., & Xie, M. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-05119-6 · Cited by 12
“Campillos et al. [5] used side-effect similarity of drugs to infer the probability of two drug sharing a target.”
BackgroundHo, S., McLachlan, A. J., Chen, T. F., Hibbs, D., & Fois, R. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.56 · Cited by 12
“A number of studies have also proposed network pharmacology as a way of understanding the on- and off-target effects of drugs.(3,4) We present a novel approach that combines the methods of pharmacoepidemiology with in silico molecular modeling to identify specific features in toxic ligands that are associated with the…”
MethodThe Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens
Bornot, A., Blackett, C., Engkvist, O., Murray, C. M., & Bendtsen, C. (2014) · SLAS DISCOVERY · doi:10.1177/1087057113518966 · Cited by 13
Systems biology visualization tools for drug target discovery
Huan, T., Wu, X., & Chen, J. Y. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003725102 · Cited by 12
“…[78] Design drugs by modeling downstream signaling molecules inside a particular pathway [30] Examine side effects of drugs on related pathways [79] Identify pathway cross-talks based on key proteins and disease-modifying genes that span multiple pathways [80] Evaluate new multi-component…”
BackgroundRepositioning of drugs using open-access data portal DTome: A test case with probenecid (Review)
AHMED, M. U., Bennett, D. J., Hsieh, T., Doonan, B. B., Ahmed, S., & WU, J. M. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2411 · Cited by 12
“Campillos et al (6) compared side-effect information between unrelated drugs to infer common protein targets.”
InfluentialKarovic, S., Shiuan, E. F., Zhang, S., Cao, H., & Maitland, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12408 · Cited by 12
Drug voyager: a computational platform for exploring unintended drug action
Oh, M., Ahn, J., Lee, T., Jang, G., Park, C., & Yoon, Y. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1558-3 · Cited by 13
“Similar properties of drugs have been used to generate new hypotheses on drug indications and have been considered the crucial basis for computational drug-repositioning approaches [5, 6].”
BackgroundInferring Drug-Protein–Side Effect Relationships from Biomedical Text
Song, M., Baek, S. H., Heo, G. E., & Lee, J. (2019) · Genes · doi:10.3390/genes10020159 · Cited by 13
How to Prepare a Compound Collection Prior to Virtual Screening
Bologa, C., Ursu, O., & Oprea, T. I. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9089-4_7 · Cited by 13
Inference on chains of disease progression based on disease networks
Lee, D. A., Kim, M.-J., & Shin, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218871 · Cited by 12
Xu, X. J., Yang, K., Zhang, F., Liu, W., Wang, Y., Yu, C., Wang, J., Zhang, K., Zhang, C., Nenadić, G., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104797 · Cited by 14
Rouillard, A. D., Wang, Z., & Ma’ayan, A. (2015) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2015.08.005 · Cited by 12
“used similarity of drug side effects to predict drug targets [142].”
MethodMizutani, S., Noro, Y., Kotera, M., & Goto, S. (2014) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2014.01.006 · Cited by 15
Cancer Gene Prediction Using a Network Approach
Wu, X., & Li, S. (2010) · Chapman & Hall/CRC mathematical and computational biology series · doi:10.1201/9781439811863-c11 · Cited by 12
“…(Sharan, Ulitsky, and Shamir 2007), especially functions of cancer genes (Hu et al. 2007), and the discovery of novel drug targets for cancer (Campillos et al. 2008; Huang and Harari 1999), since the formulation are similar thus novel methods developed for one problem may also apply to the…”
BackgroundValidation of a risk stratification tool for fall-related injury in a state-wide cohort
McCoy, T. H., Castro, V. M., Cagan, A., Roberson, A. M., & Perlis, R. H. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012189 · Cited by 12
Hameed, R., Khan, A., Khan, S., & Perveen, S. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666181009163014 · Cited by 13
Dalpé, G., & Joly, Y. (2014) · Drug Development Research · doi:10.1002/ddr.21211 · Cited by 14
“In so doing, datasets containing side effect information from package leaflets were used to create weighted associations between drugs and side effects based on the frequency occurrence of the latter [Campillos et al., 2008].”
MethodOu, Q., Jiang, X., Guo, Z., Jiang, J., Gan, Z., Han, F., & Cai, Y. (2025) · Life · doi:10.3390/life15030436 · Cited by 13
“Drug–target interactions are critical for predicting side effects [15–17].”
Zhuang, C., Sheng, C., Shin, W. S., Wu, Y., Li, J., Yao, J., Dong, G., Zhang, W., Sham, Y. Y., Miao, Z., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2521 · Cited by 11
“com/oncotarget frequently causes toxicity [13] and adverse effects [14, 15].”
Vogt, I., Prinz, J., Worf, K., & Campillos, M. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu487 · Cited by 11
Self-citationInformation Loss in Network Pharmacology
Vogt, I., & Mestres, J. (2019) · Molecular Informatics · doi:10.1002/minf.201900032 · Cited by 11
Whole proteome mapping of compound-protein interactions
Chirasani, V. R., Wang, J., Sha, C. M., Raup‐Konsavage, W. M., Vrana, K. E., & Dokholyan, N. V. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100035 · Cited by 11
“The interaction of drugs with unintended targets (off-targets) may generate adverse drug reactions (Bowes et al., 2012; Campillos et al., 2008; Roth, 2007), such as the severe side effects induced by the fatty acid amide hydrolase (FAAH) inhibitor BIA 10–2474 in a recent clinical trial (Hayes et…”
BackgroundAydın, B., Beklen, H., Arğa, K. Y., Bayraklı, F., & Turanlı, B. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01923-2 · Cited by 11
“A signature-based drug repositioning strategy was followed employing the Library of Integrated Network-based Cellular Signatures (LINCS)–L1000 data which constituted gene expression data from ~ 50 human cell lines in response to ~ 20,000 compounds [51].”
BackgroundMethodSystematic Analysis of the Associations between Adverse Drug Reactions and Pathways
Chen, X., Wang, Y., Wang, P., Lian, B., Li, C., Wang, J., Li, X., & Jiang, W. (2015) · BioMed Research International · doi:10.1155/2015/670949 · Cited by 11
“We only considered drug-target annotations with binding affinity that were lower than 10 𝜇 M [15].”
Kanji, R., Sharma, A., & Bagler, G. (2015) · Molecular BioSystems · doi:10.1039/c5mb00312a · Cited by 13
Determination of minimal transcriptional signatures of compounds for target prediction
Nigsch, F., Hutz, J., Cornett, B., Selinger, D. W., McAllister, G., Bandyopadhyay, S., Loureiro, J., & Jenkins, J. L. (2012) · EURASIP Journal on Bioinformatics and Systems Biology · doi:10.1186/1687-4153-2012-2 · Cited by 12
“There is a considerable amount of literature on target prediction methods that work from chemical structure alone or composite data types using a variety of meth-ods, and we refer the interested reader to [1-4] and the references therein.”
BackgroundA Survey of Network Representation Learning Methods for Link Prediction in Biological Network
Peng, J., Lu, G., & Shang, X. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200116145057 · Cited by 11
HNEDTI: Prediction of drug-target interaction based on heterogeneous network embedding
Lu, Z., Wang, Y., Zeng, M., & Li, M. (2019) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm47256.2019.8983181 · Cited by 11
“Campillos et al. developed a measure for side-effect similarity and integrated drug side-effect similarity and chemical similarity to infer whether two drugs share a target [10].”
BackgroundFarhana, N., Afendi, F. M., Fitrianto, A., & Wijaya, S. H. (2021) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1863/1/012067 · Cited by 16
“Side Effect Similarity Side Effect Similarity (SES) is a value developed by [5] who focused on predicting specific protein targets generally associated with the main mechanism of drug action which could then be used to predict pharmacodynamic interactions.”
BackgroundTran, T.-D., & Pham, D.-T. (2021) · Scientific Reports · doi:10.1038/s41598-021-93336-z · Cited by 11
“Equation (5) represents distributed consensus protocols proposed in the classical model of DeGroot52.”
BackgroundInfluentialSukanya, S. H., Venkatesh, T., Rao, S. J. A., Shivakumara, N., & Joy, M. N. (2021) · Chimica Techno Acta · doi:10.15826/chimtech.2021.8.4.01 · Cited by 11
“In the present study, in silico molecular docking studies were performed to predict the most effective binding among the synthesized molecules to appropriate targets [60, 61].”
MethodIdentifying problematic drugs based on the characteristics of their targets
Lopes, T. J. S., Shoemaker, J. E., Matsuoka, Y., Kawaoka, Y., & Kitano, H. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00186 · Cited by 13
“As recently demonstrated, known drugs have multiple protein off-targets, bound with enough specificity to interfere with their functions (Campillos et al., 2008; Yamanishi et al., 2008; Keiser et al., 2009; Lounkine et al., 2012).”
BackgroundXue, M., Zhang, S., Cai, C., Yu, X., Shan, L., Liu, X., Zhang, W., & Li, H. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/256782 · Cited by 11
“constructed a sideeffect similarity network to identify common protein targets of unrelated drugs, which is only applicable for marketed drugs with detailed side-effect information [19].”
BackgroundNon-negative Matrix Tri-Factorization for Data Integration and Network-based Drug Repositioning
Ceddia, G., Pinoli, P., Ceri, S., & Masseroli, M. (2019) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb.2019.8791474 · Cited by 11
“For instance, in [4] the authors used side effects to identify drugtargets connections that further lead them to drug repositioning.”
BackgroundLovrics, A., Pape, V. F. S., Szisz, D., Kalászi, A., Heffeter, P., Magyar, C., & Szakács, G. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0390-3 · Cited by 11
“For this purpose, the DTP NCI60 database serves as a unique resource, but CMap [35], SIDER [36, 37] or chemogenomic databases [38] or the calculated ADMET properties [39] could also provide the starting point to search for candidate scaffold hopping molecule pairs.”
MethodA Review of Recent Developments and Progress in Computational Drug Repositioning
Shi, W., Chen, X., & Deng, L. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200116145559 · Cited by 11
PREDICTION OF OFF-TARGET DRUG EFFECTS THROUGH DATA FUSION
Yera, E. R., Cleves, A. E., & Jain, A. N. (2013) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814583220_0016 · Cited by 12
Link Prediction through Deep Generative ModelPreprint
Wang, X.-W., Chen, Y., & Liu, Y.-Y. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/247577 · Cited by 11
Leveraging Distributed Biomedical Knowledge Sources to Discover Novel Uses for Known DrugsPreprint
Womack, F., McClelland, J., & Koslicki, D. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/765305 · Cited by 11
“While machine learning approaches to the drug repurposing problem have been proposed [16,17, 20,21,22,56,67], these methods typically use only a few sources of information, and typically only a few characteristics of a given drug and disease, such as genomic information, chemical structure information, and/or drug int…”
BackgroundMethodThe functional therapeutic chemical classification system
Croset, S., Overington, J. P., & Rebholz-Schuhmann, D. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt628 · Cited by 11
“Availability: https://www.ebi.ac.uk/chembl/ftc; https://github.com/ loopasam/ftc. Contact: croset@ebi.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online.”
BackgroundMultidimensional profiling in the investigation of small-molecule-induced cell death
Wolpaw, A. J., & Stockwell, B. R. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801430-1.00011-1 · Cited by 10
Xie, L., Kinnings, S., Xie, L., & Bourne, P. E. (2012) · Wiley eBooks · doi:10.1002/9781118274408.ch7 · Cited by 11
Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation
Ali, M. S., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., Sahebkar, A., & Kesharwani, P. (2026) · Drug Development Research · doi:10.1002/ddr.70281 · Cited by 13
“The Side Effect Resource database, which is abbreviated as SIDER, tracks drugs and drug‐related adverse effects (Campillos et al. 2008).”
Synthesis of a biological active β-hairpin peptide by addition of two structural motifs
Fischer, S., Lamping, M., Gold, M., Roettger, Y., Brödje, D., Dodel, R. C., Frantz, R., Mraheil, M. A., Chakraborty, T., & Geyer, A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.022 · Cited by 10
Application of Network Pharmacology Based on Artificial Intelligence Algorithms in Drug Development
Zhou, W., Li, X., Han, L., & Fan, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-0753-0_2 · Cited by 11
García‐Sosa, A. T., & Maran, U. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500300u · Cited by 10
El‐Shemy, H. A., Aboul-Enein, K. M., & Lightfoot, D. A. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/801501 · Cited by 10
“Improvements in effectiveness were predicted for arti�cial combinations of 2 or 3 natural products. at effect might be attributed to drug synergism rather than increased numbers of binding proteins bound (dose effects).”
BackgroundInfluentialEdberg, A., Soeria‐Atmadja, D., Laurila, J. B., Johansson, F., Gustafsson, M. G., & Hammerling, U. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200429f · Cited by 10
Chemical genetics strategies for identification of molecular targets
Botubol‐Ares, J. M., Durán‐Peña, M. J., Hernández‐Galán, R., & Collado, I. G. (2013) · Phytochemistry Reviews · doi:10.1007/s11101-013-9312-6 · Cited by 10
“Therefore, identification of relevant targets can often lead to the discovery of more specific drugs with fewer side effects (Campillos et al. 2008).”
BackgroundOpen Issues in Intelligent Personal Health Record – An Updated Status Report for 2012
Luo, G. (2013) · Journal of Medical Systems · doi:10.1007/s10916-013-9943-6 · Cited by 11
Early Repositioning Through Compound Set Enrichment Analysis: A Knowledge-Recycling Strategy
Temesi, G., Bolgár, B., Arany, Á., Szalai, C., Antal, P., & Mátyus, P. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.4 · Cited by 12
Functional genomics and networks: new approaches in the extraction of complex gene modules
Mínguez, P., & Dopazo, J. (2010) · Expert Review of Proteomics · doi:10.1586/epr.09.103 · Cited by 10
A Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug Effects
Prinz, J., Vogt, I., Adornetto, G., & Campillos, M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005111 · Cited by 11
Self-citationComputational Drug Target Screening through Protein Interaction Profiles
Vilar, S., Quezada, E., Uriarte, E., Costanzi, S., Borges, F., Viña, D., & Hripcsak, G. M. (2016) · Scientific Reports · doi:10.1038/srep36969 · Cited by 10
Predicting Target and Chemical Druggability
Oprea, T. I., & Hasselgren, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12342-x · Cited by 12
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.